---
title: "Neuroscience is becoming AbbVie's quiet powerhouse -- and management now sees $12.7 billion in sales this year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296027928.md"
description: "AbbVie has another blockbuster business emerging."
datetime: "2026-08-16T16:02:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296027928.md)
  - [en](https://longbridge.com/en/news/296027928.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296027928.md)
generator: "portal-rs"
---

# Neuroscience is becoming AbbVie's quiet powerhouse -- and management now sees $12.7 billion in sales this year

AbbVie has another blockbuster business emerging.

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.](https://longbridge.com/en/news/285600926.md)
- [AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis](https://longbridge.com/en/news/294086753.md)
- [The Bull Case For AbbVie (ABBV) Could Change Following EU Approval Of Rinvoq For Vitiligo](https://longbridge.com/en/news/294200563.md)
- [Prediction: This Stock Will Outperform the "Magnificent Seven" in the Second Half of 2026](https://longbridge.com/en/news/296903702.md)
- [China Was the Outlier to Lego's Broad-Based Revenue Growth in First Half, CEO Says](https://longbridge.com/en/news/297007458.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**